Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Shares Outstanding (Diluted Average): 2009-2025

Historic Shares Outstanding (Diluted Average) for Cytokinetics (CYTK) over the last 7 years, with Sep 2025 value amounting to $119,982.

  • Cytokinetics' Shares Outstanding (Diluted Average) rose 1.95% to $119,982 in Q3 2025 from the same period last year, while for Sep 2025 it was $119,982, marking a year-over-year increase of 1.95%. This contributed to the annual value of $111,979 for FY2024, which is 16.01% up from last year.
  • Per Cytokinetics' latest filing, its Shares Outstanding (Diluted Average) stood at $119,982 for Q3 2025, which was up 0.44% from $119,457 recorded in Q2 2025.
  • Cytokinetics' 5-year Shares Outstanding (Diluted Average) high stood at $119,982 for Q3 2025, and its period low was $71,754 during Q2 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $109,240 (2024), whereas its average is $107,480.
  • Data for Cytokinetics' Shares Outstanding (Diluted Average) shows a peak YoY climbed of 22.50% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Cytokinetics' Shares Outstanding (Diluted Average) stood at $76,886 in 2021, then rose by 16.83% to $89,825 in 2022, then increased by 7.46% to $96,524 in 2023, then climbed by 16.01% to $111,979 in 2024, then climbed by 1.95% to $119,982 in 2025.
  • Its last three reported values are $119,982 in Q3 2025, $119,457 for Q2 2025, and $118,496 during Q1 2025.